This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in France
This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Spain
This report presents the prevalence and number of hospital discharges in the UnitedStates (U.S.) as well as the surgical procedure volumes for selected cardiovascular/thoracic diseases/disorders.
This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected musculoskeletal diseases/disorders.
This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected neurological diseases/disorders.
The scope of this report includes tissue-engineered skin replacements and substitutes (i.e., epidermal equivalents, dermal equivalents, and multilayer equivalents) and active wound repair modulators.
Approximately 16.3 million adults in the United States (U.S.) suffer from coronaryheart disease (CHD), a type of cardiovascular disease that is associated with areduction in blood flow through the vasculature of the heart (ischemic heart disease).
Discoveries in molecular medicine in recent years have allowed researchers to study the genetic/chromosomal alterations that trigger the transformation of normal cells into malignant cells, which ultimately has led to the understanding that cancer—of which there are more than 100 forms—is a disease of the cellular genome.
The scope of this report includes compression therapy products (e.g., compression bandages, compression stockings, and pneumatic compression devices) and pressure reduction and relief products (e.g., specialty/integrated beds, mattress replacements, and mattress overlays).
This report presents an overview of the most common types of treatment for the benign uterine conditions of menorrhagia and uterine fibroids/polyps; among these therapies are dilation and curettage, hysterectomy, hysteroscopy, and myomectomy. Market and competitive analyses for the medical devices used in these treatments also are presented.
The United States (U.S.) market for orthopedic biomaterials for bone repair and regeneration, as covered by the scope of this report
Prosthetic vascular grafts, made of synthetic or biological materials, are used to bypass or replace segments of blood vessels in kidney failure patients requiring hemodialysis access as well as those undergoing treatment for aneurysms or vascular occlusions.
The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.
This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the EU country of France.
This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.
This report presents market and competitive analyses for selected leading contraceptive and fertility products as well as an overview of the most common types of contraceptives and fertility drugs/treatments available to women in the United States (U.S.) for reproductive management.
This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Germany.
The intensity and high acuity of the critical care environment, combined with the shortage of experienced registered nurses, means that noninvasive and minimally invasive patient monitoring products will be in great demand during the forecast period covered by this report.
This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Spain.
At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)
Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold
Macitentan is a novel dual endothelin receptor antagonist (ERA)
showing sustained receptor occupancy
KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]
Eslicarbazepine has been approved in ex-US markets including the EU for years.
We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.
These pathways can be targeted either at the cell surface receptor
level or their downstream signaling cascades. Currently, everolimus in combination with
exemestane represents a new standard of care for patients progressing on non-steroidal AIs.
HDAC inhibitors have also shown promising results For innate resistance, the combination of
fulvestrant and AI in the front line setting represents a new treatment option, particularly for
patients who present with de novo metastatic disease.
This report discusses common ophthalmic diseases/disorders, prevalence, estimated U.S. procedure volumes, leading energy-based (laser and phacoemulsification, or “phaco”) ophthalmic surgical systems and their features, and novel technologies. A detailed U.S. market analysis, competitive analysis, and company profiles of selected U.S. competitors are also provided.
The study was just closed early, as LCZ696 increased time to first occurrence of either
cardiovascular death or heart failure hospitalization, though details have not been released.
We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different
assumptions about what the study found.
Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML.
Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML.
Drugs and drug candidates discussed:
palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor
The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and soon-to-be approved, direct-acting antivirals for Hepatitis C.
Diagnostics/diagnostic techniques discussed:
etarfolatide/folic acid, BRCA mutation testing
Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.
Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.
In 1995, GlaxoSmithKline’s Flolan (epoprostenol) became the first therapy to be specifically approved for the orphan disease of pulmonary arterial hypertension (PAH).
Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data
Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!